Icosavax (NASDAQ:ICVX) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Icosavax (NASDAQ:ICVX) in a report published on Tuesday morning, TipRanks reports. The firm issued a buy rating and a $50.00 target price on the stock. Jefferies Financial Group also issued estimates for Icosavax’s Q3 2021 earnings at ($0.51) EPS, Q4 2021 earnings at ($0.49) EPS, FY2021 earnings at ($2.26) EPS, FY2022 earnings at ($1.85) EPS and FY2023 earnings at ($2.11) EPS.

Other analysts have also recently issued research reports about the company. Cowen began coverage on Icosavax in a research report on Monday, August 23rd. They set an outperform rating for the company. William Blair started coverage on Icosavax in a research report on Monday, August 23rd. They set an outperform rating and a $45.70 price objective for the company. Finally, Evercore ISI started coverage on Icosavax in a research report on Monday, August 23rd. They issued an outperform rating and a C$50.00 price target for the company.

Icosavax stock opened at $33.06 on Tuesday. Icosavax has a one year low of $21.70 and a one year high of $49.99.

Icosavax (NASDAQ:ICVX) last posted its quarterly earnings data on Monday, September 13th. The company reported ($2.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($1.96). Analysts predict that Icosavax will post -2.4 earnings per share for the current fiscal year.

About Icosavax

Icosavax Inc is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company’s virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc is based in SEATTLE.

See Also: Trade War

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.